MARKET

COGT

COGT

Cogent Biosciences Inc
NASDAQ
40.67
+0.23
+0.57%
After Hours: 40.67 0 0.00% 16:04 07/28 EDT
OPEN
40.53
PREV CLOSE
40.44
HIGH
40.73
LOW
39.02
VOLUME
1.13M
TURNOVER
--
52 WEEK HIGH
43.73
52 WEEK LOW
10.38
MARKET CAP
6.95B
P/E (TTM)
-18.8873
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at COGT last week (0720-0724)?
Weekly Report · 1d ago
Weekly Report: what happened at COGT last week (0713-0717)?
Weekly Report · 07/20 09:27
Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q1 2026 Update
Seeking Alpha · 07/19 07:10
Weekly Report: what happened at COGT last week (0706-0710)?
Weekly Report · 07/13 09:27
Cogent Biosciences (COGT) Files FDA Application As Bezuclastinib Hype Meets A Pricey Valuation
Simply Wall St · 07/10 13:35
Is Bezuclastinib’s FDA Filing And Disease-Modifying Data Altering The Investment Case For Cogent Biosciences (COGT)?
Simply Wall St · 07/09 02:35
Weekly Report: what happened at COGT last week (0629-0703)?
Weekly Report · 07/06 09:29
3 Reasons Cogent Biosciences (COGT) Looks Pricey After Its FDA Filing
Simply Wall St · 07/02 13:47
More
About COGT
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.

Webull offers Cogent Biosciences Inc stock information, including NASDAQ: COGT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COGT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading COGT stock methods without spending real money on the virtual paper trading platform.